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Background: In sub-Saharan Africa where genotypic anti-retroviral (ARV) drug resistance testing is rarely 
performed and poor adherence is blamed for the inability to achieve viral suppression and treatment failure, 
programmatic approaches to preventing and handling these are essential. This study was aimed at assessing the 
virological outcomes among HIV patients receiving second-line anti-retroviral therapy (ART) in Southwestern 
Nigeria.  
Methodology: This was a 5-year observational retrospective study of randomly selected people living with HIV 
(PLWHIV) who have been switched to second-line ART for at least six months before the commencement of the 
study in multiple comprehensive ART sites across the three levels of care, in Ondo and Ekiti States, Southwestern 
Nigeria, from January 2015 to December 2019. Quantitative viral load analysis was done using polymerase chain 
reaction (PCR) assay. Data were analyzed using the Statistical Package for Social Sciences (SPSS) version 24.0.  
Results: A total of 249 (71 males and 178 females) subjects eligible for the study were recruited using simple 
random sampling technique. The mean age (± SD) of the subjects was 44.21 ± 11.45 years. The mean number 
of years the patients have been on ART regimen was 7.92 ± 2.68 years. The mean number of years the patients 
were on first line ART regimen before being switched to second line was 4.27 ± 2.63 years. Patients with viral 
load <1000 RNA copies/ml (suppressed viral load) were 216 (86.7%) out of which 113 (45.4%) had viral load 
<20 RNA copies/ml while 33 (13.3%) had viral load >1000 RNA copies/ml (unsuppressed viral load or virological 
failure). 
Conclusion: About 13% of the patients on second line ART had unsuppressed viral load of more than 1000 RNA 
copies/ml indicating virological failure. Thus, critical factors such as poor adherence to ART and drug resistance 
chiefly contributing to virological failure have to be routinely checked. 
 
Keywords: suppression, ART, resistance, virological, failure, Nigeria 
Received Apr 26, 2021; Revised Jun 9, 2021; Accepted Jun 13, 2021 
 
Copyright 2021 AJCEM Open Access. This article is licensed and distributed under the terms of the Creative Commons Attrition 4.0 International License 
<a rel="license" href="http://creativecommons.org/licenses/by/4.0/", which permits unrestricted use, distribution and reproduction in any medium, 
provided credit is given to the original author(s) and the source. Editor-in-Chief: Prof. S. S. Taiwo 
 
Preuve d'échec virologique chez les patients sous traitement 
antirétroviral de deuxième intention dans le sud-ouest du 
Nigeria: une indication pour le test de résistance aux 
médicaments contre le VIH 
 
*Usman, S.O., Ajayi, O.M., Ebiekura, O., Egbonrelu, N., Ebhojie, G., et Ariyo, A.O. 
 
Initiatives de santé publique de l'APIN, Abuja, Nigéria 




Contexte: En Afrique subsaharienne, où les tests génotypiques de résistance aux antirétroviraux (ARV) sont 
rarement effectués et où une mauvaise observance est imputée à l'incapacité d'obtenir la suppression virale et 
l'échec du traitement, des approches programmatiques pour les prévenir et les gérer sont essentielles. Cette 
étude visait à évaluer les résultats virologiques chez les patients VIH recevant un traitement antirétroviral (TAR) 
de deuxième intention dans le sud-ouest du Nigeria.                     
Méthodologie: Il s'agissait d'une étude rétrospective d'observation de 5 ans portant sur des personnes vivant 




avec le VIH (PVVIH) sélectionnées au hasard et passées à un TAR de deuxième intention pendant au moins six 
mois avant le début de l'étude dans plusieurs sites de TAR complets aux trois niveaux. de soins, dans les États 
d'Ondo et d'Ekiti, dans le sud-ouest du Nigéria, de janvier 2015 à décembre 2019. L'analyse quantitative de la 
charge virale a été effectuée à l'aide d'un test de réaction en chaîne par polymérase (PCR). Les données ont été 
analysées à l'aide du logiciel Paquet statistique pour les sciences sociales (SPSS) version 24.0.                 
Résultats: Un total de 249 (71 hommes et 178 femmes) sujets éligibles à l'étude ont été recrutés à l'aide d'une 
technique d'échantillonnage aléatoire simple. L'âge moyen (± ET) des sujets était de 44,21±11,45 ans. Le nombre 
moyen d'années pendant lesquelles les patients ont été sous traitement antirétroviral était de 7,92±2,68 ans. Le 
nombre moyen d'années pendant lesquelles les patients étaient sous traitement antirétroviral de première ligne 
avant de passer en deuxième ligne était de 4,27 ± 2,63 ans. Les patients avec une charge virale <1000 copies 
d'ARN/ml (charge virale supprimée) étaient 216 (86,7%) dont 113 (45,4%) avaient une charge virale <20 copies 
d'ARN/ml tandis que 33 (13,3%) avaient une charge virale >1000 ARN copies/ml (charge virale non supprimée 
ou échec virologique).                                    
Conclusion: Environ 13 % des patients sous TAR de deuxième ligne avaient une charge virale non supprimée 
de plus de 1000 copies d'ARN/ml indiquant un échec virologique. Ainsi, les facteurs critiques tels qu'une mauvaise 
adhésion au TARV et la résistance aux médicaments contribuant principalement à l'échec virologique doivent être 
systématiquement vérifiés. 
 




In many countries of the sub-Saharan 
Africa, hundreds of thousands of people living 
with HIV (PLHIV) have initiated antiretroviral 
therapy (ART), which has led to a reduction in 
the death toll related to HIV. While a majority 
of these patients have achieved treatment 
success on first-line therapy, the number of 
those requiring second-line protease inhibitor-
based drugs is increasing due to failure of the 
first-line therapy (1,2). The challenge with 
patients on second-line ART in resource-
limited settings, where genotypic drug resis- 
tance testing is rarely performed in programs 
for patients before start of treatment (3), has 
been in the event of treatment failure, due to 
limited availability and financial implication of 
third-line therapy (4,5).  
In Nigeria, the government in partner- 
ship with international collaborators, has since 
responded to the epidemic scourge of the HIV 
infection through different intervention prog- 
rams, including the establishment and scale-
up of national ART (6,7) as well as domesti- 
cated policy documents that are in line with 
international best standards. Although the 
“National Guidelines for HIV Prevention 
Treatment and Care” of 2016 has provided a 
guide on management of patients failing the 
second-line ART, the challenge of unavaila- 
bility of drug sensitivity testing has also been 
highlighted (8).  
Available studies assessing virological 
failure among patients on second-line ART in 
resource-limited settings have had different 
definitions for virological failure (4). In the 
Nigerian ART program, viral load of <1000 
RNA copies/ml is regarded as evidence of viral 
suppression while a persistently detectable 
viral load of ≥ 1000 copies/ml on two consecu- 
tive viral load measurements within a 3-month 
interval, with Enhance Adherence Counselling 
(EAC) between measurements, after at least 
six months on ART, is considered virological 
failure (8). To reap maximum benefits from 
the second-line ART as well as plan for better 
management of patients requiring this line of 
ART, including drug sensitivity testing, there is 
need for extensive study of patients on this 
therapy, which appears to be limited in the 
Nigerian context.  
During a median follow up period of 29 
months of PLHIV in Southern Vietnam, 18.4% 
of the patients experienced treatment failure 
with four WHO stage IV AIDS events and 
13.5% death recorded during the period (9). 
In Myanmar, where long-term outcomes of 
second-line ART of 824 patients was followed 
up, it was reported that of 52 patients who 
received viral load testing, 19 had virological 
failure and at the end of a seven year follow 
up, 88 (11%) patients died with 680 (83%) 
still under care (10).  
The objective of this study is to assess 
the virological outcomes among HIV patients 
receiving second-line ART in Southwestern 
Nigeria, with the hypothesis that opportunistic 
infection and ARV adherence level do not have 
significant impact on viral load outcome. 
 
Materials and method: 
 
Study setting and design 
This was a 5-year retrospective study 
of paediatric, adolescent and adult HIV-
infected patients who have been switched to 
second-line ART for at least six months as at 
the commencement of the study in multiple 
comprehensive ART sites across the three 
levels of care in Ondo and Ekiti States, 
Southwestern Nigeria, from January 2015 to 
December 2019. 
 
Sample size and method of sampling 
The sample size for the study was 
calculated using the formula, n = Z2PQ/d2 for 
population more than 10,000 (11) at 95% 
confidence interval (Z=1.96), 0.05 precision, 
and prevalence rate of Nigerians currently 
living with HIV/AIDS in Southwestern Nigeria 
of 1.2% (12). A total of 249 eligible HIV-
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infected patients were selected by simple 
random sampling technique.   
 The inclusion criteria were patients 
living with HIV of all age groups and gender 
who have been on second-line anti-retroviral 
therapy (ART) at least six months as at the 
time of the study, and have at least one 
documented viral load result after the comm- 
encement of second-line ART. 
 
Data collection 
Relevant demographic ad clinical data 
such as age, gender, functional status, WHO 
clinical staging, ART regimen (at start and 
current) and ART adherence level were 
obtained from the patients’ electronic medical 
record (EMR) with triangulation from patients’ 
case folders. Confidentiality was strictly main- 
tained throughout the study period in a 
computerized form through adequate security 
provision regarding data storage on the com- 
puter system.  
 
Statistical analysis 
The data analysis was done using the 
Statistical Package for the Social Sciences 
(SPSS) for windows version 24.0 software 
(SPSS Inc; Chicago, IL, USA). Frequency 
counts was generated for all variables and 
statistical test of significance for categorical 
data was performed with Chi-square test. 
Other data were expressed as mean ± 
standard deviation and analysed using the 
analysis of variance (ANOVA) with multiple 
comparisons done by Post Hoc Bonferroni test. 
Statistical significance was fixed at p < 0.05 




Socio-demographic and clinical data 
A total of 249 subjects (71 males and 
178 females) eligible for the study were 
recruited. Majority of the subjects (54.7%) are 
in the age range 35-49 years with mean age 
(± SD) of 44.21 ± 11.45 years (Table 1). The 
mean number of years the patients have been 
on ART regimen is 7.92±2.68 years. The mean 
number of years the patients were on first line 
ART regimen before being switched to second 
line is 4.27±2.63 years. All the subjects were 
active on antiretroviral treatment.  
 Using the WHO strategy, those with 
viral load <1000 RNA copies/ml (suppressed 
viral load) were 216 (86.7%), out of which 113 
(45.4%) had viral load <20 RNA copies/ml, 
while 33 (13.3%) had viral load >1000 RNA 
copies/ml (unsuppressed viral load). At the 
commencement of ART, 151 (60.6%) patients 
were on zidovudine, lamivudine and nevira- 
pine regimen, 91 (36.5%) on tenofovir, lami- 
vudine and efavirenz, while 7 (2.8%) were on 
zidovudine, lamivudine and efavirenz. 
Discussion: 
 
This study outcome shows that 86.7% 
of the patients had suppressed viral load 
based on the viral load outcome using the 
WHO strategy for surveillance and monitoring 
of HIV drug resistance in low-and-middle-
income-countries (LMICs), which indicated 
that viral load of <1000 RNA copies/ml should 
be taken as evidence of viral suppression (13). 
This outcome differs from that of Myanmar 
study which reported 36.5% virological failure 
among HIV patients on second line ART (10) 
as against 13.3% in our study. This finding 
implies generally that more patients in our 
study demonstrated treatment improvement 
with impressive suppression rate (86.7%) that 
can be alluded to the use of the protease 
inhibitors, and better drug adherence with 
91.2% having good adherence (≥ 95%) than 
when they were on first line regimen where 
the adherence level was 82.3% and supp- 
ression rate was 83.1%. Our finding from 
monthly dose assessment carried out revealed 
that missed doses in patients on ARV drugs 
taken twice daily was ≤ 3 in a month while 
missed doses for ARV drugs taken once daily 
was only once a month. This finding may be 
due to reported general minimal side effects of 
the protease inhibitors in the combination, 
especially atazanavir/ritonavir (14).  
 The Chi-square analysis and odd ratio 
(OR) showed that the presence of oppor- 
tunistic infections did not have significant 
impact on viral load outcome in our study [χ² 
=1.15, OR: 1.05 (95% CI: 0.11 –1.76), p= 
0.283], which may be occasioned by the fact 
that only about 5% of the patients had repor- 
ted mild cases of opportunistic infections. 
Generally, opportunistic infections are caused 
by non-pathogenic micro-organisms which 
become pathogenic when the immune system 
is impaired by an unrelated disease. Their 
prevention or effective treatment when dete- 
cted has always formed a core part of the HIV 
treatment and management program, with the 
use of antibiotics and antifungal medications 
in order to significantly reduce morbidity and 
mortality thus prolonging the lives of the 
patients (15).    
 However, antiretroviral (ARV) adhe- 
rence level significantly affected the viral load 
outcome of the patients, as patients on second 
line ART having 91.2% good adherence (> 
95% adherence) had suppressed viral load of 
86.7% compared to patients on first line ART 
having 82.3% good adherence with supp- 
ressed viral load of 83.1% (χ²=16.03, OR: 
2.15 (95% CI 0.37-7.31), p<0.001]. This indi- 
cates that patients on second-line ART tend to 
miss fewer doses, which may be due to the 
reported  general  minimal  side  effects  of the 
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Table 1: Socio-demographic and clinical data of patients living with HIV on second line anti-retroviral therapy in Ondo and Ekiti States, Nigeria 
 
Variables Frequency (%) 
Age group (years) 
15 – 19 
20 - 24 
25 – 29 
30 – 34 
35 – 39 
40 – 44 
45 – 49 
50 – 54 


























First line antiretroviral therapy (ART) 
Tenofovir, Lamivudine & Efavirenz 
Zidovudine, Lamivudine & Efavirenz 




Second line antiretroviral therapy (ART) 
Zidovudine, Lamivudine & Lopinavir/Ritonavir 
Abacavir, Lamivudine & Atazanavir/Ritonavir 
Abacavir, Lamivudine & Lopinavir/Ritonavir 
Tenofovir, Lamivudine & Atazanavir/Ritonavir 


























































Adherence on first line ART 
Good (≥ 95%) 
Fair (85 – 94%) 




Adherence on second line ART 
Good (≥ 95%) 
Fair (85 – 94%) 




Viral load outcome on first line ART 
Suppressed viral load 
Unsuppressed viral load 
207 (83.1) 
42 (16.9) 
Viral load outcome on second line ART 
Suppressed viral load 
Unsuppressed viral load 
216 (86.7) 
33 (13.3) 
Current tuberculosis status 
No signs of tuberculosis 
Presumptive tuberculosis with signs 
230 (92.4) 
19 (7.6) 
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Table 2: Impact of opportunistic infections and anti-retroviral therapy adherence on viral load outcome 
Variables X2* OR 95% CI p value 
Impact of opportunistic infection on viral load 
outcome 
1.15 1.05 0.11-1.76 0.283 
Impact of ARV drugs adherence level on viral 
load outcome 
16.03 2.15 0.37-7.31 <0.001 
*Null hypothesis is rejected when the test statistic (χ²) is greater than the critical value of 3.84; X2 = Chi square; OR = Odd ratio; CI = Confidence 
interval  
 
protease inhibitors in the combination, espe- 
cially atazanavir/ritonavir (14), resulting in 
higher compliance and therefore higher supp- 
ression rates. Good adherence (> 95%) has 
always been associated with the beliefs regar- 
ding the positive impact of the medications on 




This study shows that about 13% of 
the HIV-infected patients on second line ART 
had unsuppressed viral load of more than 
1,000 RNA copies/ml, indicating virological 
failure. With critical factors such as poor adhe- 
rence to ART and drug resistance chiefly cont- 
ributing to virological failure, routine adhe- 
rence and viral load monitoring as well as the 
availability of HIV drug resistance testing to 
determine the resistance pattern of a specific 
HIV strain to ARV drugs in use will ensure that 
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